TOP TEN perturbations for 1553602_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553602_at
Selected probe(set): 1553602_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553602_at (1553602_at) across 6673 perturbations tested by GENEVESTIGATOR:

basal cell carcinoma study 3 / normal epidermal keratinocytes

Relative Expression (log2-ratio):9.1188
Number of Samples:4 / 2
Experimental basal cell carcinoma study 3
Primary tumor tissue from the eyelid of patients with basal cell carcinoma (BCC).
Control normal epidermal keratinocytes
Normal human epidermal keratinocytes (NHEK) (Kurabo Ind., Ltd., Osaka, Japan) cultured in HuMedia-KB2 medium at 37°C in humidified air containing 5% CO2.

expO breast cancer study 1 (medullary carcinoma, NOS; primary) / expO breast cancer study 1 (inflammatory carcinoma; primary)

Relative Expression (log2-ratio):-6.286377
Number of Samples:2 / 2
Experimental expO breast cancer study 1 (medullary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS).
Control expO breast cancer study 1 (inflammatory carcinoma; primary)
Primary tumor tissue samples obtained from the breast of patients with inflammatory carcinoma.

VTX-2337 study 1 / untreated monocyte sample

Relative Expression (log2-ratio):6.1938334
Number of Samples:3 / 3
Experimental VTX-2337 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control untreated monocyte sample
Peripheral blood monocytes isolated from healthy donors.

VTX-2337 study 1 / 3M-055 study 1

Relative Expression (log2-ratio):5.9609957
Number of Samples:3 / 3
Experimental VTX-2337 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control 3M-055 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM 3M-055 drug, which represents a TLR7 (Toll-like receptor 7) agonist.

breast cancer study 3 / normal mammary gland tissue

Relative Expression (log2-ratio):-5.891019
Number of Samples:17 / 7
Experimental breast cancer study 3
Breast basal tumor samples.
Control normal mammary gland tissue
Normal breast tissue samples.

Merkel cell carcinoma study 3 (metastatic) / normal skin tissue

Relative Expression (log2-ratio):-5.719697
Number of Samples:11 / 64
Experimental Merkel cell carcinoma study 3 (metastatic)
Metastatic tumor tissue from different metastatic sites (skin, lymph node, parotid gland) of patients with Merkel cell carcinoma of the skin.
Control normal skin tissue
Normal skin samples from healthy donors.

Merkel cell carcinoma study 3 (primary) / normal skin tissue

Relative Expression (log2-ratio):-5.678154
Number of Samples:19 / 64
Experimental Merkel cell carcinoma study 3 (primary)
Primary tumor tissue from the skin of patients with Merkel cell carcinoma.
Control normal skin tissue
Normal skin samples from healthy donors.

breast cancer study 50 (subtype II) / breast cancer study 50 (subtype I)

Relative Expression (log2-ratio):5.657959
Number of Samples:34 / 37
Experimental breast cancer study 50 (subtype II)
Primary tumor tissue samples obtained from the breast of patients with breast cancer with KFSYSCC subtype II. Samples were collected at the Koo Foundation Sun-Yat-Sen Cancer Center (KFSYSCC) between 1991 and 2004. Exclusion criteria: patients with follow-up periods shorter than three years, with the exception of patients who died of the disease within three years of the initial treatment. KFSYSCC subtype II:predominantly negative for ER, variable for PR expression, predominantly positive for HER2, larger tumors dominate (T-stage), propensity to develop distant metastases (47%), increased expressions of cell cycle/proliferation genes, high risk of distant recurrence
Control breast cancer study 50 (subtype I)
Primary tumor tissue samples obtained from the breast of patients with breast cancer with KFSYSCC subtype I. Samples were collected at the Koo Foundation Sun-Yat-Sen Cancer Center (KFSYSCC) between 1991 and 2004. Exclusion criteria: patients with follow-up periods shorter than three years, with the exception of patients who died of the disease within three years of the initial treatment. KFSYSCC subtype I:predominantly negative for ER, variable for PR expression, predominantly negative for HER2, in concordance with chemosensitive basal-like intrinsic type, CMF yielded survival outcome similar to those of CAF, increased expressions of cell cycle/proliferation genes, high risk of distant recurrence

glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):5.4401035
Number of Samples:2 / 4
Experimental glioma study 17 (glioblastoma; unsorted)
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

breast cancer study 3 / normal organelle sample

Relative Expression (log2-ratio):-5.3176413
Number of Samples:17 / 12
Experimental breast cancer study 3
Breast basal tumor samples.
Control normal organelle sample
Normal organelle samples.